iNK cell therapy for EBV complications after stem cell transplant
Part of Blood & lymphatic clinical trials.
This trial studies whether a type of immune cell called iNK can help treat chronic active EBV or EBV-related high inflammation that remains after a stem cell transplant. It may be an option for people who still have signs of EBV in their blood, spinal fluid, bone marrow, or scans after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic active EBV or EBV-related high inflammation (HLH) and are eligible for a stem cell transplant
- You have signs of EBV in your blood, spinal fluid, bone marrow, or on scans before transplant
- You are 65 years old or younger and are in fairly good health (able to do daily activities)
- Your heart, kidneys, and liver are working well enough (no severe heart disease, cirrhosis, or active hepatitis)
- If you have HLH, your condition must have improved at least partially with prior treatment
- You do not have uncontrolled infections other than EBV, active internal bleeding, or are in another clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, golidocitinib and selinexor, given together to treat chronic active Epstein-Barr virus disease (CAEBVD). The goal is to see if this combination can help control the disease better than current options.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.